3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Phase 1
1
Status
Recruiting
8
Terminated
3
Not yet recruiting
2
Active not recruiting
2
Suspended
1
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Leukemia, Myeloid, Acute
1
Bites and Stings
1
Interventions
pembrolizumab
111
Carboplatin
45
Nivolumab
41
Paclitaxel
34
Cyclophosphamide
32
Cisplatin
32
Gemcitabine
30
atezolizumab
27
venetoclax
25
Specimen Handling
25
Magnetic Resonance Spectroscopy
24
Pemetrexed
23
fludarabine
22
Docetaxel
22
Biopsy
22
Radiotherapy
21
Ipilimumab
21
Bevacizumab
21
Azacitidine
21
Radiosurgery
18
Dexamethasone
18
durvalumab
17
Fluorouracil
17
Cetuximab
16
fludarabine phosphate
14
Trastuzumab
14
tislelizumab
13
Leucovorin
13
Cytarabine
13
olaparib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Terminated
×
Hydroxyurea
×
1 year
×
Clear all
NCT05853458
2026-04-30
HU-F-AIM
Novartis
Phase 4
Terminated
76 enrolled
NCT06063317
2026-03-06
OASIS
Imugene Limited
Phase 1
Terminated
25 enrolled
NCT03860844
2025-09-09
ISAKIDS
Sanofi
Phase 2
Terminated
67 enrolled
25 charts